With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna’s stock has seen an extended downtrend since peaking above $480 in late 2021. After crashing to below $70 in November last year, the stock experienced a strong medium-term rally that took it ...

Moderna said it plans to cut $1.1 billion in expenses by 2027 as it charts a path forward after the rapid decline of its Covid business. The biotech company said it expects 10 new product ...

Citing skyrocketing COVID spread, the FDA announced in late August that it had approved Pfizer’s Comirnaty and Moderna’s ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even. The Cambridge-based ...

Vaccine developer Moderna said it was cutting research and development spending and pushed back its time frame for breaking even. The company on Thursday also forecast a 2025 revenue range that ...

Moderna, the Massachusetts-based biotech company that rocketed into the global spotlight during the development of its COVID-19 vaccine, announced plans on Thursday to cut costs and refocus on ...

Moderna Therapeutics (NASDAQ: MRNA) was once the darling of the healthcare space for investors. The company emerged as one of the biggest names of the COVID-19 pandemic with its vaccine.

Moderna was a huge pandemic name, but has struggled since the earlier days of the health crisis. The company is looking to introduce new products and then lower its R&D budget. Even after its sell ...